4.5 Article

Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients

Journal

BONE MARROW TRANSPLANTATION
Volume 48, Issue 8, Pages 1091-1097

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2013.13

Keywords

hematopoietic cell transplantation; autologous; allogeneic; fertility preservation; infertility; pregnancy

Funding

  1. Public Health Service from the National Cancer Institute, the National Heart, Lung and Blood Institute [U24-CA76518]
  2. National Institute of Allergy and Infectious Diseases
  3. NHLBI [5U01HL069294]
  4. NCI
  5. Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
  6. Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
  7. Allos, Inc.
  8. Amgen, Inc.
  9. Angioblast
  10. Ariad
  11. Be the Match Foundation
  12. Blue Cross and Blue Shield Association
  13. Buchanan Family Foundation
  14. CaridianBCT
  15. Celgene Corporation
  16. CellGenix
  17. GmbH
  18. Children's Leukemia Research Association
  19. Fresenius-Biotech North America, Inc.
  20. Gamida Cell Teva Joint Venture Ltd.
  21. Genentech, Inc.
  22. Genzyme Corporation
  23. GlaxoSmithKline
  24. HistoGenetics, Inc.
  25. Kiadis Pharma
  26. Leukemia and Lymphoma Society
  27. Medical College of Wisconsin
  28. Merck Co, Inc.
  29. Millennium: The Takeda Oncology Co.
  30. Milliman USA, Inc.
  31. Miltenyi Biotec, Inc.
  32. National Marrow Donor Program
  33. Optum Healthcare Solutions, Inc.
  34. Osiris Therapeutics, Inc.
  35. Otsuka America Pharmaceutical, Inc.
  36. RemedyMD
  37. Sanofi
  38. Seattle Genetics
  39. Sigma-Tau Pharmaceuticals
  40. Soligenix, Inc.
  41. StemCyte, A Global Cord Blood Therapeutics Co
  42. Stemsoft Software, Inc.
  43. Swedish Orphan Biovitrum
  44. Tarix Pharmaceuticals
  45. Teva Neuroscience, Inc.
  46. THERAKOS, Inc.
  47. Wellpoint, Inc.
  48. National Institute for Health Research [NF-SI-0611-10275] Funding Source: researchfish

Ask authors/readers for more resources

Physician practice variation may be a barrier to informing hematopoietic cell transplant (HCT) recipients about fertility preservation (FP) options. We surveyed HCT physicians in the United States to evaluate FP knowledge, practices, perceptions and barriers. Of the 1035 physicians invited, 185 completed a 29-item web-survey. Most respondents demonstrated knowledge of FP issues and discussed and felt comfortable discussing FP. However, only 55% referred patients to an infertility specialist. Most did not provide educational materials to patients and only 35% felt that available materials were relevant for HCT. Notable barriers to discussing FP included perception that patients were too ill to delay transplant (63%), patients were already infertile from prior therapy (92%) and time constraints (41%). Pediatric HCT physicians and physicians with access to an infertility specialist were more likely to discuss FP and to discuss FP even when prognosis was poor. On analyses that considered physician demographics, knowledge and perceptions as predictors of referral for FP, access to an infertility specialist and belief that patients were interested in FP were observed to be significant. We highlight variation in HCT physician perceptions and practices regarding FP. Physicians are generally interested in discussing fertility issues with their patients but lack educational materials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available